Preclinical discovery and development of colesevelam for the treatment of type 2 diabetes

.
Source: Expert Opinion on Drug Discovery - Category: Drugs & Pharmacology Authors: Source Type: research

Related Links:

Conditions:   Type 2 Diabetes;   NASH - Nonalcoholic Steatohepatitis;   NAFLD Interventions:   Device: Duodenal Mucosal Resurfacing (DMR) Procedure;   Device: Sham Sponsor:   Fractyl Laboratories, Inc. Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conditions:   Chronic Kidney Diseases;   Type 2 Diabetes Intervention:   Sponsor:   Medlior Health Outcomes Research Ltd Not yet recruiting
Source: ClinicalTrials.gov - Category: Research Source Type: clinical trials
Conclusions: The findings of this study will present the existing evidence for the effect of RYGBS for patients with T2DM. Systematic review registration: INPLASY202040127.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
This study will be conducted according to the preferred reporting items for systematic review and meta-analysis protocols 2015 statement. The protocol of this systematic review and meta-analysis was registered on international platform of registered systematic review and meta-analysis protocols (No. 202040136). The following electronic bibliographic databases will be searched from inception: EMBASE, MEDLINE, Web of Science, Cochrane Central, China National Knowledge Infrastructure, Wanfang and China Science and Technology Journal Database, and Clinical Trials (ClinicalTrials.gov). A search strategy will be developed using ...
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
Conclusions: This study will help to build proposals that aim at providing high quality RCTs in the management of LSGT in OP with T2DM. Systematic review registration: INPLASY202040128.
Source: Medicine - Category: Internal Medicine Tags: Research Article: Study Protocol Systematic Review Source Type: research
Authors: Al-Rawahi A PMID: 32489679 [PubMed]
Source: Oman Medical Journal - Category: Middle East Health Tags: Oman Med J Source Type: research
Authors: Yahaya TO, Ufuoma SB Abstract Single gene mutations have been implicated in the pathogenesis of a form of diabetes mellitus (DM) known as the maturity-onset diabetes of the young (MODY). However, there are diverse opinions on the suspect genes and pathophysiology, necessitating the need to review and communicate the genes to raise public awareness. We used the Google search engine to retrieve relevant information from reputable sources such as PubMed and Google Scholar. We identified 14 classified MODY genes as well as three new and unclassified genes linked with MODY. These genes are fundamentally embedde...
Source: Oman Medical Journal - Category: Middle East Health Tags: Oman Med J Source Type: research
Publication date: Available online 3 June 2020Source: Pharmacological ResearchAuthor(s): Peyman Nowrouzi-Sohrabi, Reza Tabrizi, Shahla Rezaei, Fatemeh Jafari, Kamran Hesami, Mehdi Abedi, Mohammad Jalali, Pedram Keshavarzi, Saeed Shahabi, Ali Asghar Kolahi, Kristin Carson-Chahhoud, Amirhossein Sahebkar, Saeid Safiri
Source: Pharmacological Research - Category: Drugs & Pharmacology Source Type: research
Cardiovascular disease (CVD) is a major contributor to the morbidity and mortality associated with type 2 diabetes mellitus (T2DM). With T2DM growing in pandemic proportions, there will be profound healthcare implications of CVD in person with diabetes. The ideal drugs to improve outcomes in T2DM are those having antiglycemic efficacy in addition to cardiovascular (CV) safety, which has to be determined in appropriately designed CV outcome trials as mandated by regulatory agencies. Available evidence is largely supportive of metformin’s CV safety and potential CVD risk reduction effects, whereas sulfonylureas are eit...
Source: Cardiology in Review - Category: Cardiology Tags: Review Articles Source Type: research
In this study, 42 patients with type 2 diabetes were randomly allocated to intervention and control groups and received either 3  g/day dill powder or placebo (3 capsules/day, 1 g each). Fasting blood sugar, insulin, homeostatic model assessment of insulin resistance, lipid profile, high-sensitivity C-reactive protein, total antioxidant capacity, malondialdehyde and gastrointestinal symptoms were measured in all of the su bjects at baseline and postintervention.ResultsThe dill powder supplementation significantly decreased the mean serum levels of insulin, homeostatic model assessment of insulin resistance, l...
Source: Trials - Category: Research Source Type: clinical trials
More News: Diabetes | Diabetes Type 2 | Drugs & Pharmacology | Endocrinology | Welchol